KR20140059236A - Hcv 프로테아제 억제제의 결정 형태 - Google Patents

Hcv 프로테아제 억제제의 결정 형태 Download PDF

Info

Publication number
KR20140059236A
KR20140059236A KR1020147006888A KR20147006888A KR20140059236A KR 20140059236 A KR20140059236 A KR 20140059236A KR 1020147006888 A KR1020147006888 A KR 1020147006888A KR 20147006888 A KR20147006888 A KR 20147006888A KR 20140059236 A KR20140059236 A KR 20140059236A
Authority
KR
South Korea
Prior art keywords
compound
hydrate
diffraction pattern
rti
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020147006888A
Other languages
English (en)
Korean (ko)
Inventor
그레고리 엘. 뷰트너
로버트 엠. 주니어 웬슬로우
에릭 제이. 초이
클린턴 스콧 슐츠
제레미 스콧
후안 디. 아레돈도
로라 아르티노
Original Assignee
머크 샤프 앤드 돔 코포레이션
머크 샤프 앤드 돔 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 머크 샤프 앤드 돔 코포레이션, 머크 샤프 앤드 돔 리미티드 filed Critical 머크 샤프 앤드 돔 코포레이션
Publication of KR20140059236A publication Critical patent/KR20140059236A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic
    • C07C35/04—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic containing a three or four-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/04—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/32—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C271/34—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/14—Preparation of carboxylic acid esters from carboxylic acid halides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/013—Esters of alcohols having the esterified hydroxy group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/126—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cephalosporin Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020147006888A 2011-08-19 2012-08-16 Hcv 프로테아제 억제제의 결정 형태 Withdrawn KR20140059236A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161525462P 2011-08-19 2011-08-19
US61/525,462 2011-08-19
US201161533439P 2011-09-12 2011-09-12
US61/533,439 2011-09-12
US201161533915P 2011-09-13 2011-09-13
US61/533,915 2011-09-13
US201161539540P 2011-09-27 2011-09-27
US61/539,540 2011-09-27
PCT/US2012/051168 WO2013028465A1 (en) 2011-08-19 2012-08-16 Crystal forms of a hcv protease inhibitor

Publications (1)

Publication Number Publication Date
KR20140059236A true KR20140059236A (ko) 2014-05-15

Family

ID=47746773

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020147006888A Withdrawn KR20140059236A (ko) 2011-08-19 2012-08-16 Hcv 프로테아제 억제제의 결정 형태
KR1020147006858A Withdrawn KR20140053330A (ko) 2011-08-19 2012-08-16 마크로락탐의 제조를 위한 방법 및 중간체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020147006858A Withdrawn KR20140053330A (ko) 2011-08-19 2012-08-16 마크로락탐의 제조를 위한 방법 및 중간체

Country Status (11)

Country Link
US (3) US9242917B2 (https=)
EP (3) EP2744331A4 (https=)
JP (2) JP2014521750A (https=)
KR (2) KR20140059236A (https=)
CN (2) CN103889439A (https=)
AU (2) AU2012299218A1 (https=)
BR (2) BR112014003798A2 (https=)
CA (2) CA2844388A1 (https=)
MX (2) MX2014001944A (https=)
RU (2) RU2014110400A (https=)
WO (3) WO2013028471A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2744331A4 (en) 2011-08-19 2015-01-21 Merck Sharp & Dohme METHOD AND INTERMEDIATE PRODUCTS FOR THE MANUFACTURE OF MACROLACTAMEN
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
EA025560B1 (ru) 2012-10-19 2017-01-30 Бристол-Майерс Сквибб Компани Ингибиторы вируса гепатита с
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9617310B2 (en) 2013-03-15 2017-04-11 Gilead Sciences, Inc. Inhibitors of hepatitis C virus
US9873707B2 (en) 2013-10-18 2018-01-23 Merck Sharp & Dohme Corp. Methods and intermediates for preparing macrolactams
WO2015095437A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Methods and intermediates for the preparation of macrolactams
PL3636649T3 (pl) 2014-01-24 2024-05-06 Turning Point Therapeutics, Inc. Diaryle makrocykliczne jako modulatory kinaz białkowych
EP3151850A4 (en) * 2014-06-06 2017-11-29 AbbVie Inc. Crystal forms
ES2864839T3 (es) 2015-07-02 2021-10-14 Turning Point Therapeutics Inc Macrociclos de diarilo quirales como moduladores de proteína quinasas
JP6917974B2 (ja) * 2015-07-06 2021-08-11 ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ジアリール大環状多形
FI3733187T3 (fi) * 2015-07-21 2024-12-18 Turning Point Therapeutics Inc Kiraalinen diaryylimakrosykli ja sen käyttö syövän hoidossa
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
BR112019001607A2 (pt) 2016-07-28 2019-04-30 Tp Therapeutics, Inc. inibidores macrocíclicos de quinases
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
EP4717317A2 (en) 2017-06-20 2026-04-01 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
US11286264B2 (en) 2017-07-28 2022-03-29 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof
LT3728271T (lt) 2017-12-19 2022-12-12 Turning Point Therapeutics, Inc. Makrocikliniai junginiai, skirti ligų gydymui
CN111057045A (zh) * 2019-12-18 2020-04-24 安徽红杉生物医药科技有限公司 Hcv ns3/4a蛋白酶抑制剂中间体及其合成方法、应用
CN112174982A (zh) * 2020-09-10 2021-01-05 上海希迈医药科技有限公司 一种洛普替尼晶型及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871868A (en) 1987-03-11 1989-10-03 Takeda Chemical Industries, Ltd. Production of substituted acetylenic compounds
GB9207987D0 (en) 1992-04-10 1992-05-27 Smithkline Beecham Plc Novel container and closure
US5716960A (en) * 1995-01-13 1998-02-10 U.S. Bioscience Inc. And Individuals Crystalline trimetrexate salts and the process for making the same
ZA98879B (en) * 1997-02-04 1998-08-03 Ono Pharmaceutical Co Omega-cycloalkyl-prostaglandin e2 derivatives
NO317155B1 (no) 1997-02-04 2004-08-30 Ono Pharmaceutical Co <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater
CN102372704B (zh) * 2005-02-18 2014-10-08 田边三菱制药株式会社 脯氨酸衍生物的盐，其溶剂合物，及其生产方法
WO2006102087A2 (en) 2005-03-22 2006-09-28 Merck & Co., Inc. Hcv protease substrates
CA2606195C (en) 2005-05-02 2015-03-31 Merck And Co., Inc. Hcv ns3 protease inhibitors
UA90909C2 (en) * 2005-07-20 2010-06-10 Мерк Шарп Энд Домэ Корп. Hcv ns3 protease inhibitors
AR057456A1 (es) 2005-07-20 2007-12-05 Merck & Co Inc Inhibidores de la proteasa ns3 del vhc
NZ565269A (en) 2005-08-01 2010-03-26 Merck & Co Inc Macrocyclic peptides as HCV NS3 protease inhibitors
EP2018146A2 (en) 2006-03-07 2009-01-28 The Procter and Gamble Company Compositions for oxidatively dyeing keratin fibers and methods for using such compositions
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
AU2007309488B2 (en) 2006-10-24 2012-10-11 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
AU2007309546A1 (en) 2006-10-24 2008-05-02 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. HCV NS3 protease inhibitors
US8377874B2 (en) 2006-10-27 2013-02-19 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
BRPI0718161A2 (pt) * 2006-10-27 2013-11-26 Merck & Co Inc Composto, composição farmacêutica, e, uso do composto.
SG174809A1 (en) 2007-05-03 2011-10-28 Intermune Inc Macrocyclic compounds useful as inhibitors of hepatitis c virus
AU2008277377B2 (en) 2007-07-19 2013-08-01 Msd Italia S.R.L. Macrocyclic compounds as antiviral agents
CA2714604A1 (en) 2008-02-25 2009-09-03 Merck Sharp & Dohme Corp. Macrocyclic hcv ns3 protease inhibitors
WO2009131196A1 (ja) * 2008-04-24 2009-10-29 武田薬品工業株式会社 置換ピロリジン誘導体およびその用途
WO2009132202A2 (en) * 2008-04-24 2009-10-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
WO2009134624A1 (en) 2008-04-28 2009-11-05 Merck & Co., Inc. Hcv ns3 protease inhibitors
EA019327B1 (ru) 2008-07-22 2014-02-28 Мерк Шарп Энд Домэ Корп. Макроциклическое хиноксалиновое соединение в качестве ингибитора протеазы вгс ns3
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
EP2470189A4 (en) * 2009-08-27 2013-01-23 Merck Sharp & Dohme METHOD FOR PRODUCING PROTEASE INHIBITORS OF HEPATITIS C VIRUS
EP2744331A4 (en) 2011-08-19 2015-01-21 Merck Sharp & Dohme METHOD AND INTERMEDIATE PRODUCTS FOR THE MANUFACTURE OF MACROLACTAMEN

Also Published As

Publication number Publication date
AU2012299223A1 (en) 2014-02-27
KR20140053330A (ko) 2014-05-07
EP2744336A4 (en) 2014-12-31
WO2013028471A1 (en) 2013-02-28
CN103874414A (zh) 2014-06-18
MX2014001945A (es) 2014-03-27
US9073825B2 (en) 2015-07-07
US9238604B2 (en) 2016-01-19
US20140243519A1 (en) 2014-08-28
US9242917B2 (en) 2016-01-26
JP2014524442A (ja) 2014-09-22
EP2744507A1 (en) 2014-06-25
EP2744331A4 (en) 2015-01-21
RU2014110400A (ru) 2015-09-27
CA2844388A1 (en) 2013-02-28
BR112014003802A2 (pt) 2017-06-13
US20140200343A1 (en) 2014-07-17
JP2014521750A (ja) 2014-08-28
BR112014003798A2 (pt) 2017-03-01
AU2012299218A1 (en) 2014-02-20
WO2013028465A1 (en) 2013-02-28
CA2844386A1 (en) 2013-02-28
EP2744336A1 (en) 2014-06-25
MX2014001944A (es) 2014-03-27
EP2744331A1 (en) 2014-06-25
RU2014110399A (ru) 2015-09-27
EP2744336B1 (en) 2017-07-05
WO2013028470A1 (en) 2013-02-28
US20140206605A1 (en) 2014-07-24
EP2744507A4 (en) 2015-01-28
CN103889439A (zh) 2014-06-25

Similar Documents

Publication Publication Date Title
KR20140059236A (ko) Hcv 프로테아제 억제제의 결정 형태
JP6524355B2 (ja) Ｔｌｒ７アゴニストとしての７−（チアゾール−５−イル）ピロロピリミジン化合物
KR100652535B1 (ko) Ｉｍｐｄｈ 효소의 억제제
ES2470568T3 (es) Inhibidores macroc�clicos del virus de la hepatitis C
CN102414199B (zh) 二芳基醚
JP6034802B2 (ja) 大環状ラクタムの調製のための方法および中間体
CA2899763C (en) Nucleoside phosphoramidate compound and use thereof
TWI542585B (zh) Ｃ型肝炎病毒抑制劑
EP3816163A1 (en) Cell necrosis inhibitor, preparation method therefor and use thereof
WO2016127916A1 (zh) 作为长效dpp-iv抑制剂的取代的氨基六元饱和杂脂环类
CN114555607A (zh) 一类靶向蛋白质水解通路的功能分子及其制备和应用
WO2022171072A1 (zh) 一种二氢嘧啶类化合物、其制备方法及其应用
WO2025016441A1 (zh) 新型GalNAc的靶向递送片段及其制备和应用
WO2015095430A1 (en) Methods and intermediates for the preparation of macrolactams
EP3498712B1 (en) Spirocyclic indolone polyethylene glycol carbonate compound, composition, preparation method and use thereof
RU2793918C2 (ru) Ингибитор некроза клеток, способ его получения и применения
CN106967141A (zh) 核苷氨基磷酸酯化合物及其医药组合物和用途
HK1136824B (en) Macrocyclic inhibitors of hepatitis c virus

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140314

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid